Toronto-based medical imaging company MolecuLight has sold its clinical oncology business to Photonamic GmbH & Co KG for an undisclosed amount. Launched in 2013 by CSO Ralph DaCosta, MolecuLight develops fluorescent imaging technology for clinical and commercial applications. Its initial solution, MolecuLight i:X, is a handheld imaging device for assessing wounds. Photonamic, a German pharmaceutical affiliate of Japan’s SBI Holdings Inc, previously partnered with MolecuLight in the oncology field. It said the deal will expand its research and development activities. Moleculight has been backed since its founding by Canadian healthcare technology venture capital firm iGan Partners and other investors.